The analysis focuses on Hims & Hers stock, which has experienced a 29% decline in the last 30 days. Three factors influencing the stock are mentioned: President Trump's announcement on weight-loss drug price reductions, concerns about compounded versions of weight loss treatments impacting competition, and the relationship with Novo Nordisk. The CEO's stock sales are also a negative sentiment driver, generating skepticism among investors. The current market price is around $35, while the analyst's DCF valuation indicates an intrinsic value of $44. Market multiples show a forward P/E of 55, which is on the lower end historically. The price to OCF is 20, also on the lower end. Given growth prospects and profitability expansion, the analyst upgrades HIMS to a buy on November 21st, 2025.